Similar articles

• Pretransplantation pharmacokinetic assessments to predict posttransplantation dosing requirements in renal transplant recipients: what is known?

  van Maarseveen E, van Zuilen AD. van Maarseveen E, et al. Clin Pharmacol Ther. 2013 Apr;93(4):306-7. doi: 10.1038/clpt.2012.214. Epub 2012 Oct 24. Clin Pharmacol Ther. 2013. PMID: 23299646 No abstract available.
• Response to "CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients".

  de Jonge H, Kuypers DR. de Jonge H, et al. Clin Pharmacol Ther. 2013 Aug;94(2):202-3. doi: 10.1038/clpt.2013.94. Epub 2013 May 9. Clin Pharmacol Ther. 2013. PMID: 23665867 No abstract available.
• CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients.

  Santoro AB, Struchiner CJ, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Suarez-Kurtz G. Santoro AB, et al. Clin Pharmacol Ther. 2013 Aug;94(2):201-2. doi: 10.1038/clpt.2013.68. Epub 2013 Apr 2. Clin Pharmacol Ther. 2013. PMID: 23588314 No abstract available.
• In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.

  de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. de Jonge H, et al. Clin Pharmacol Ther. 2012 Sep;92(3):366-75. doi: 10.1038/clpt.2012.109. Epub 2012 Aug 8. Clin Pharmacol Ther. 2012. PMID: 22871995
• Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study.

  van Maarseveen EM, Crommelin HA, Mudrikova T, van den Broek MP, van Zuilen AD. van Maarseveen EM, et al. Transplantation. 2013 Jan 27;95(2):397-402. doi: 10.1097/TP.0b013e3182734651. Transplantation. 2013. PMID: 23250333